**
In a concerning revelation, documents obtained through a Freedom of Information Act request have shed light on a meeting between top officials at the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson, which took place on 17 June. This meeting was part of the Trump administration’s ongoing efforts to bolster Bayer’s legal standing in its fight against numerous lawsuits claiming that its glyphosate-based herbicides, notably Roundup, are linked to cancer. As regulatory practices come under scrutiny, this interaction raises questions about the extent of corporate influence within government decision-making processes.
Meeting of Corporate Power and Regulatory Oversight
The discussions at the EPA included the potential for “supreme court action” regarding glyphosate, a widely used herbicide under scrutiny for its health implications. Bayer is currently facing litigation from tens of thousands of individuals who allege that their use of glyphosate products led to cancer. Critics argue that the company has neglected to adequately warn users about these risks, a claim supported by various studies over the years.
Bayer’s strategy to mitigate its legal troubles hinges on persuading the Supreme Court that, without an EPA mandate for cancer warnings, the company cannot be held liable for failing to disclose such risks. To date, while some courts have sided with Bayer, others have rejected this argument, including the Biden administration’s solicitor general. In stark contrast, the Trump administration has actively defended Bayer’s position, signalling a troubling alignment between corporate interests and governmental authority.
Unveiling the Regulatory Process
According to an internal EPA email outlining the meeting’s agenda, Bayer’s team aimed to discuss “legal/judicial issues,” including their litigation status and labelling options. This meeting occurred shortly before the Supreme Court requested input from the Justice Department on whether it should consider Bayer’s case, further indicating the intertwined nature of corporate lobbying and regulatory actions.
Nathan Donley, environmental health science director at the Center for Biological Diversity, expressed grave concerns over the implications of such meetings, stating, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” This highlights a significant conflict of interest, where the health and safety of the public may be secondary to corporate profit margins.
Subsequent Actions and Implications
Following the June meeting, the Trump administration’s support for Bayer intensified. In December, the solicitor general filed a brief urging the Supreme Court to hear Bayer’s case, which was subsequently accepted, with a hearing set for 27 April. This was accompanied by a White House invocation of the Defense Production Act to safeguard glyphosate production, further cementing the administration’s commitment to corporate interests.
Moreover, the actions taken by the Trump administration following the meeting raise ethical concerns about the regulatory landscape. Legal experts like Whitney Di Bona have questioned the propriety of such secretive meetings, emphasising, “We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup.”
The Broader Context of Corporate Influence
The meeting between Bayer’s CEO and EPA officials is emblematic of a broader trend in which corporate leaders enjoy unprecedented access to government regulators, often at the expense of public health. Naomi Oreskes, a Harvard professor who studies corporate influence on regulation, noted that this pattern suggests a disparity in how industry representatives are treated compared to the very citizens who may suffer from their products.
Activists like Zen Honeycutt, founder of Moms Across America, have also voiced their frustrations, stating, “Coercion by chemical companies on our regulatory agencies is nothing new.” Her organisation has engaged with the EPA multiple times, yet they have seen little progress on calls for restricting or banning harmful pesticides.
Why it Matters
The implications of this meeting extend far beyond Bayer’s legal battles; they reflect a troubling dynamic in which corporate interests can dictate regulatory frameworks, potentially compromising public health and safety. As the EPA appears to align more closely with the needs of powerful corporations rather than the welfare of American citizens, it underscores an urgent need for transparency and accountability within our regulatory agencies. The ongoing glyphosate litigation serves as a critical reminder of the importance of safeguarding public health against corporate influence, making it imperative that citizens remain vigilant in holding their government accountable.
